Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Kanarek, Naama

Boston Children'S Hospital
United States

Mechanistic Study of Methotrexate-Induced Oxidative Distress in Neurons and the CSF 5R01CA282477-02 John Clifford, Ph.D.
Kanarek, Naama

Boston Children'S Hospital
United States

Mechanistic Study of Methotrexate-Induced Oxidative Distress in Neurons and the CSF 5R01CA282477-02 John Clifford, Ph.D.
Kanetsky, Peter A

H. Lee Moffitt Cancer Ctr & Res Inst
United States

A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers 5R01CA291735-02 Claire Zhu, Ph.D.
Kang, Dongkyun

University Of Arizona
United States

Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy 1R01CA301271-01 Rachel Altshuler, Ph.D.
Kang, Dongkyun

University Of Arizona
United States

Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy 1R01CA301271-01 Rachel Altshuler, Ph.D.
Kanwal, Fasiha

Baylor College Of Medicine
United States

Risk Stratification for and Early Detection of Liver Cancer 5U01CA230997-08 Sidney Fu, M.D.
Kassie, Fekadu

University Of Minnesota
United States

Targeting tumor cell mitochondria for the prevention and treatment of lung cancer 1R01CA285608-01A1
Kelleher, Sarah

Duke University
United States

Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients 5R01CA291888-02 Brennan Streck, Ph.D., RN, M.P.H.
Kelleher, Sarah

Duke University
United States

Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients 5R01CA291888-02 Brennan Streck, Ph.D., RN, M.P.H.
Kelleher, Sarah

Duke University
United States

Randomized Controlled Trial of a Hybrid-Delivered Cognitive Behavioral Symptom Management and Activity Coaching Intervention for Stem Cell Transplant Patients 5R01CA291888-02 Brennan Streck, Ph.D., RN, M.P.H.
Kelleher, Sarah

Duke University
United States

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings 5R21CA273832-02 Brennan Streck, Ph.D., RN, M.P.H.
Kelleher, Sarah

Duke University
United States

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings 5R21CA273832-02 Brennan Streck, Ph.D., RN, M.P.H.
Khan, Seema Ahsan

Northwestern University At Chicago
United States

Northwestern Cancer Prevention Consortium 2UG1CA242643-07 Donald Johnsey
Khan, Seema Ahsan

Northwestern University At Chicago
United States

Determinants of transdermal drug delivery to the normal and the radiated breast 5R01CA235647-05 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Khasabov, Sergey G

University Of Minnesota
United States

Treatment of cancer pain by lipid mediator Resolvin D1: role of Prostaglandin and Endocannabinoid signaling 5R01CA263777-05 Rachel Altshuler, Ph.D.